NCT05044117
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Feb 2022); last known: Recruiting
Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
- Eligibility criteria expanded, about 2 words
- Start date changed from estimate of Oct 2021 to Oct 18, 2021
- Site details revised
- Collaborators: 8 to 9
- Notable Eligibility criteria expanded, about 2 words
- Secondary endpoints: details revised at 1 of 5 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression-free survival
Timeframe: 2 years
Secondary (5)
Overall survival
Distant failure-free survival
Locoregional failure-free survival
Adverse events
Patient reported quality-of-life score
Arms and interventions
Clinical observationNo intervention
The standard treatment followed by clinical observation.
Metronomic capecitabineExperimental
The standard treatment followed by a maintenance therapy with capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year.
Drugs: Capecitabine
Sites
1 site in 1 country
- Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, China